Form 4: Arcturus Therapeutics Executive Sells Shares Under 10b5-1 Trading Plan

Pad Chivukula, Chief Scientific Officer & COO of Arcturus Therapeutics, sold 114 shares of common stock at $45 per share on June 5, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On June 5, 2024, Pad Chivukula, the Chief Scientific Officer & COO of Arcturus Therapeutics Holdings Inc., sold 114 shares of the company's common stock.
• The sale was executed at a price of $45 per share.
• This transaction was conducted under a Rule 10b5-1 trading plan previously adopted by Mr. Chivukula.
• Following the transaction, Mr. Chivukula still beneficially owns 447,334 shares of Arcturus Therapeutics.
• The sale was reported on a Form 4 filing with the Securities and Exchange Commission on June 7, 2024.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing reporting a stock sale by an executive under a pre-arranged trading plan. It doesn't inherently indicate positive or negative sentiment.

Industry Context

Sales by company executives are a normal part of corporate governance. The use of a 10b5-1 trading plan suggests the executive is selling shares in a pre-planned manner to avoid accusations of insider trading.

Stakeholder Impact

• The stock sale by an executive could have a minor impact on shareholder sentiment, but the use of a 10b5-1 plan mitigates concerns about insider trading.

Key Dates